FIELD: biotechnology.
SUBSTANCE: disclosed are the use of a non- depleting anti-CD6 antibody that specifically binds to domain 1 of CD6, for the treatment of an infectious disease that leads to a cytokine storm or cytokine release syndrome, for the treatment of an infectious disease caused by a coronavirus, which leads to a cytokine storm or a cytokine release syndrome, and for the treatment of COVID-19. Also disclosed is a kit for treating a subject against COVID-19.
EFFECT: inventions extend the range of products for treating and reducing the negative consequences caused by infectious agents, especially coronaviruses, wherein said negative consequences include triggering a cytokine storm or cytokine release syndrome.
17 cl, 9 dwg, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNODOMINANT PROTEINS AND FRAGMENTS IN MULTIPLE SCLEROSIS | 2019 |
|
RU2828590C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| COMBINED COMPOSITION CONTAINING FGF-18 COMPOUND | 2016 |
|
RU2745453C2 |
| COMBINATION OF MONOCLONAL ANTIBODIES OF OX40 AGONIST AND 4-1BB AGONIST FOR CANCER TREATMENT | 2017 |
|
RU2748949C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
